Company:  CURIS INC (CRIS)
Form Type:  10-Q
Filing Date:  10/31/2011 
CIK:  0001108205 
Address:  4 MAGUIRE ROAD 
City, State, Zip:  LEXINGTON, Massachusetts 02421 
Telephone:  617-503-6500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.27  
Change: 
-0.04 (-1.73%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$195.10M
Description of Business
We are an oncology-focused company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Our primary investment is focused on the development of our proprietary targeted cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase or HDAC and phosphatidylinositol-3-kinase, or PI3K enzymes and CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis, or IAP proteins. Our collaborators F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing and continuing the further development of Erivedge� (vismodegib), a first-in-class orally-administered small molecule Hedgehog pathway inhibitor, and our licensee Debiopharm S.A.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I
      FINANCIAL STATEMENTS
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
          BALANCE SHEET
          INCOME STATEMENT
      Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II-OTHER INFORMATION
      Item 1A. Risk Factors
      Item 6. EXHIBITS
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
BROKERAGE PARTNERS